Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases.

Webster, R; Murphy, A; Bygrave, H; Ansbro É; Grobbee, DE; Perel, P

Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases.

Webster, R

Murphy, A Bygrave, H Ansbro É Grobbee, DE Perel, P

Permalink

Publisher:: Ubiquity Press, Ltd.
Publication Type:: Journal Article
Citation:: Global heart, 2020, 15, (1), pp. 57
Issue Date:: 2020-08-19

Recently Added

	Filename	Description	Size
	860-2579-1-PB.pdf	Published version	939.86 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is new to OPUS and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Webster, R https://orcid.org/0000-0002-7444-3037
dc.contributor.author	Murphy, A
dc.contributor.author	Bygrave, H
dc.contributor.author	Ansbro É
dc.contributor.author	Grobbee, DE
dc.contributor.author	Perel, P
dc.date.accessioned	2020-10-03T08:37:18Z
dc.date.available	2020-10-03T08:37:18Z
dc.date.issued	2020-08-19
dc.identifier.citation	Global heart, 2020, 15, (1), pp. 57
dc.identifier.issn	2211-8160
dc.identifier.issn	2211-8179
dc.identifier.uri	http://hdl.handle.net/10453/143049
dc.description.abstract	Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.
dc.format	Electronic
dc.language	eng
dc.publisher	Ubiquity Press, Ltd.
dc.relation.ispartof	Global heart
dc.relation.isbasedon	10.5334/gh.860
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.title	Implementing Fixed Dose Combination Medications for the Prevention and Control of Cardiovascular Diseases.
dc.type	Journal Article
utslib.citation.volume	15
utslib.location.activity	England
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	/University of Technology Sydney/Faculty of Business
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	recently_added	*
dc.date.updated	2020-10-03T08:36:49Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	15
utslib.start-page	57
utslib.citation.issue	1

Abstract:

Highlights: - Despite clinical evidence of its effectiveness in secondary prevention of cardiovascular disease, uptake of fixed dose combination therapy (FDCs) for CVD has been poor.- A symposium was held bringing together stakeholders on this issue, including from academia, government and NGOs.- The conclusion made was that what is now needed to improve implementation of FDCs is country-specific health systems analyses to design appropriate implementation strategies.- Implementation strategies must look beyond listing on the WHO Essential Medicines List to consider approaches to improving FDC availability, accessibility, affordability, and adherence.- Strategies might include incorporation of FDCs into the WHO HEARTS technical package, simplified treatment and monitoring algorithms, decentralisation of medicine dispensing and task-sharing for treatment management.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/143049